Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Study Summary

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Conditions

Myeloproliferative Neoplasms

Interventions / Drugs

INCA036978 Standard disease-directed therapy

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment218 participants

Primary Completion—

Lead SponsorIncyte Corporation

Data Retrieved2026-04-11 02:55:29.647667+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.